Pharmaceuticals, Biotechnology and Life Sciences
– Patient characteristics are consistent with other DLB studies – PURCHASE, N.Y., Oct. 31, 2024 (GLOBE NEWSWIRE) — Cognition Therapeutics,…
Participants in the Phase 2a study experienced rapid and meaningful decreases in depressive symptoms Suicidal ideation decreased by 80% SPN-820…
Company to Host Conference Call Today, October 31, at 4:30pm ETBOCA RATON, Fla., Oct. 31, 2024 (GLOBE NEWSWIRE) — INmune…
CHAPEL HILL, N.C., Oct. 31, 2024 (GLOBE NEWSWIRE) — Tenax Therapeutics, Inc. (Nasdaq: TENX), a Phase 3, development-stage pharmaceutical company…
ASHBURN, Va., Oct. 31, 2024 (GLOBE NEWSWIRE) — Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage…
First patient dosed in Phase 1 clinical trial evaluating ZW171 in advanced mesothelin (MSLN)-expressing cancers Preclinical data presented on ZW220…
Quarter Highlights Include Key Additions to Management Team and Extension of Cash Runway into 2027 with $31M Raise via ATM…
Winner to be Presented at BIO-Europe 2024 in Stockholm, SwedenROCKVILLE, Md., Oct. 31, 2024 (GLOBE NEWSWIRE) — Theriva™ Biologics (NYSE…
IBSRELA generates $40.6 million in net product sales revenue; Company expects full year 2024 IBSRELA net sales revenue to be between…
Iovance also to Participate in Upcoming November ConferencesSAN CARLOS, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) — Iovance Biotherapeutics, Inc. (NASDAQ:…